News
CTMX
2.180
-0.46%
-0.010
CytomX Therapeutics: A Balanced Hold Rating Amidst Financial Uncertainty and Clinical Progress
TipRanks · 4d ago
Weekly Report: what happened at CTMX last week (0318-0322)?
Weekly Report · 4d ago
CytomX Therapeutics Welcomes New Director and Updates Bylaws
TipRanks · 6d ago
Press Release: CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
CytomX Therapeutics appoints Dr. Zhen Su to the company's board of directors. Dr. Su is an experienced physician executive and leader in the development of oncology therapeutics. He is currently chief executive officer of Marengo Therapeutic. CytomX is a leader in conditionally activated, localized biologics.
Dow Jones · 03/21 12:00
CytomX Therapeutics Announces Milestone Achievement In PROBODY T-Cell Engaging Bispecific Collaboration With Astellas; Triggers $5M Payment To CytomX
CytomX and Astellas to collaborate on T-cell engaging bispecifics. First clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX. Program is one of several ongoing collaboration projects in broad Cytom X-Astellas alliance.
Benzinga · 03/18 12:13
Weekly Report: what happened at CTMX last week (0311-0315)?
Weekly Report · 03/18 09:17
CytomX Therapeutics Braces for Increased Compliance Costs as it Outgrows ‘Smaller Company’ Status
TipRanks · 03/13 06:02
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. Fell 11% to $16.72 on Tuesday. Asana reported soft FY25 revenue guidance. ClearOne, Inc., rose 168.4% in the mid-day session. Regulus Therapeutics Inc. Shares rose 74.3% after posting strong quarterly results.
Benzinga · 03/12 18:07
CytomX falls as Bristol Myers ends deal for cancer therapy
CytomX Therapeutics shares fell as Bristol Myers ends deal for cancer therapy. Bristol Myers Squibb (BMY) has ended a research collaboration to jointly develop an experimental drug for solid tumors. The company is eligible to receive up to $1.8B in milestone payments.
Seeking Alpha · 03/12 17:26
CytomX Therapeutics Price Target Cut to $3.25/Share From $3.30 by BMO Capital
Dow Jones · 03/12 15:21
CytomX Therapeutics Is Maintained at Market Perform by BMO Capital
Dow Jones · 03/12 15:21
BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25
Benzinga · 03/12 15:11
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
Acadia Pharmaceuticals stock is down 17.6% after the Phase 3 clinical trial of pimavanserin failed to meet its primary endpoint. The drug is a treatment for negative symptoms of schizophrenia. Shares of CytomX Therapeutics stock, ClearOne stock and Bit Digital stock are also down on Tuesday.
Investorplace · 03/12 13:30
Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today?
CytomX Therapeutics reported revenue of $26.6 million in Q4 2023. The company spent most of 2023 cutting costs to continue operations. CTMX stock is down 18.3% as of Tuesday morning. ClearOne, Bit Digital and Nukkleus are also in the news today.
Investorplace · 03/12 13:12
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Regulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. Assure Hldgs stock increased by 73.02% in the pre- market session. Telomir Pharmaceuticals and Bioventus also moved upwards.
Benzinga · 03/12 13:05
CytomX Therapeutics Price Target Maintained With a $3.00/Share by Wedbush
Dow Jones · 03/12 12:34
Wedbush Reiterates Neutral on CytomX Therapeutics, Maintains $3 Price Target
Benzinga · 03/12 12:24
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
TipRanks · 03/12 12:20
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Oracle Corporation rose sharply in today's pre-market trading after the company reported upbeat earnings for its fiscal third quarter. Oracle's third-quarter revenue increased 7% year-over-year to $13.3 billion. Singularity Future Technology Ltd. Shares rose 88.6% to $5.94 in pre- market trading.
Benzinga · 03/12 12:11
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
ClearOne stock is soaring over 71% after announcing a special one-time cash dividend. Nukkleus stock is rocketing more than 78% in pre-market trading. A dividend, a share buyback announcement, earnings and more are moving stocks this morning. Biggest Pre-Market Stock Movers are the biggest winners and losers for Tuesday.
Investorplace · 03/12 11:34
More
Webull provides a variety of real-time CTMX stock news. You can receive the latest news about Cytomx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies (TCBs), and immune modulators such as cytokines and checkpoint inhibitors (CPIs). Its clinical pipeline also includes cancer immunotherapeutic candidates. Its product candidates include CX-2029, CX-904, CX-2051, CX-801 and BMS-986288. Its CX-2029 is a Probody ADC targeting CD71 for the treatment of patients with squamous non-small cell lung carcinoma (sqNSCLC) and esophageal cancers.